Role of per-operative milrinone on pulmonary hypertension having mitral valve replacement.

  • Shahbaz Ahmad Khilji Faisalabad Institute of Cardiology, Faisalabad.
  • Shuja Tahir Faisalabad Institute of Cardiology, Faisalabad.
  • Shahid Abbas Faisalabad Institute of Cardiology, Faisalabad.
Keywords: Left Ventricular Ejection Fraction, Mitral Valve Disease, Mitral Valve Replacement, Pulmonary Hypertension, Right Ventricular Failure

Abstract

Objective: To determine the role of perioperative milrinone on pulmonary hypertension in patients with mitral valve disease undergoing mitral valve replacement surgery. Study Design: Randomized Control Trial. Setting: Department of Cardiac Surgery, Faisalabad Institute of Cardiology, Faisalabad. Period: June 2019 to June 2020. Material & Methods: A total of 80 patients with mitral valve disease who underwent mitral valve replacement were included. The patients were divided into a control group of 40, who were not administered milrinone, and a study group of 40 who received milrinone perioperatively. TVPG, LVEF and NYHA class were recorded preoperatively and postoperatively and were compared. Results: In the study group, postoperative LVEFs and NYHA class were not statistically significant in both groups while postoperative TVPG was significantly lower in study group as compare to control group and is statistically significant (P<0.001). Conclusion: Our study concludes that milrinone can be used as an effective therapy to reduce pulmonary pressure in patients with pulmonary hypertension undergoing mitral valve replacement surgery.

Author Biographies

Shahbaz Ahmad Khilji, Faisalabad Institute of Cardiology, Faisalabad.

MBBS, FCPS (Cardiac Surgery)

Associate Professor Cardiac Surgery

Shuja Tahir, Faisalabad Institute of Cardiology, Faisalabad.

B.Sc, MBBS

Resident MS Cardiac Surgery

Shahid Abbas, Faisalabad Institute of Cardiology, Faisalabad.

MBBS, MCPS (Medicine), FCPS (Cardiology)

Associate Professor Cardiology

Published
2021-01-10